Researchers at the Kennedy Institute have developed a new computational framework that allows simultaneous analysis of gene ...

近日，广东省农业科学院动科所家禽育种团队在鸡原始生殖细胞技术研究方面取得新进展，相关研究成果以“Single-cell RNA-seq offer new insights into the cell fate decision of the ...

Jan. 28, 2025 — A team of stem cell scientists have successfully used embryonic stem cell engineering to create a bi-paternal mouse -- a mouse with two male parents -- that lived until adulthood.

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe ...

Fate Therapeutics FATE reported a loss of 31 cents per share (excluding impairment loss) in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 44 cents. The company ...

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 29.55% and 46.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?